Business Description
Lavipharm SA
ISIN : GRS246003008
Total Employee Number:
285Compare
Compare
Traded in other countries / regions
LAVI.GreeceBXA0.Germany IPO Date
2022-08-16Description
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.58 | |||||
Debt-to-EBITDA | 2.24 | |||||
Interest Coverage | 4.89 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.58 | |||||
Beneish M-Score | -2.22 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -41.5 | |||||
3-Year EBITDA Growth Rate | -31.4 | |||||
3-Year EPS without NRI Growth Rate | -13.3 | |||||
3-Year Book Growth Rate | 11.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 91.73 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 38.57 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.97 | |||||
9-Day RSI | 70.21 | |||||
14-Day RSI | 62.57 | |||||
3-1 Month Momentum % | 5.09 | |||||
6-1 Month Momentum % | 17.94 | |||||
12-1 Month Momentum % | 103.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.21 | |||||
Quick Ratio | 0.7 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 237.7 | |||||
Days Sales Outstanding | 104.73 | |||||
Days Payable | 94.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.29 | |||||
Dividend Payout Ratio | 0.69 | |||||
Forward Dividend Yield % | 1.29 | |||||
5-Year Yield-on-Cost % | 1.3 | |||||
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 1.19 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 48.42 | |||||
Operating Margin % | 14.39 | |||||
Net Margin % | 9.57 | |||||
EBITDA Margin % | 23.26 | |||||
FCF Margin % | 3.27 | |||||
OCF Margin % | 10.65 | |||||
ROE % | 10.85 | |||||
ROA % | 4.7 | |||||
ROIC % | 6.34 | |||||
3-Year ROIIC % | 207.97 | |||||
ROC (Joel Greenblatt) % | 26.57 | |||||
ROCE % | 10.72 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 44.72 | |||||
PE Ratio without NRI | 55.52 | |||||
PS Ratio | 4.36 | |||||
PB Ratio | 4.81 | |||||
Price-to-Tangible-Book | 38.75 | |||||
Price-to-Free-Cash-Flow | 134.16 | |||||
Price-to-Operating-Cash-Flow | 41.28 | |||||
EV-to-EBIT | 32.8 | |||||
EV-to-EBITDA | 21.07 | |||||
EV-to-Revenue | 4.91 | |||||
EV-to-FCF | 133.95 | |||||
Price-to-GF-Value | 1.5 | |||||
Price-to-Graham-Number | 9.69 | |||||
Earnings Yield (Greenblatt) % | 3.04 | |||||
FCF Yield % | 0.74 | |||||
Forward Rate of Return (Yacktman) % | -48.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lavipharm SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 62.584 | ||
| EPS (TTM) (€) | 0.036 | ||
| Beta | 2.0315 | ||
| 3-Year Sharpe Ratio | 0.85 | ||
| 3-Year Sortino Ratio | 1.98 | ||
| Volatility % | 50.74 | ||
| 14-Day RSI | 62.57 | ||
| 14-Day ATR (€) | 0.057586 | ||
| 20-Day SMA (€) | 1.421 | ||
| 12-1 Month Momentum % | 103.66 | ||
| 52-Week Range (€) | 0.706 - 1.85 | ||
| Shares Outstanding (Mil) | 170.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lavipharm SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lavipharm SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| EUR 0.020000 Cash Dividend | 2026-07-20 | 1.38 (+0.88%) | ||
| EUR 0.020000 Cash Dividend | 2025-07-17 | 0.75 (+0.00%) |
Show
Entries
Lavipharm SA Frequently Asked Questions
What is Lavipharm SA(FRA:BXA0)'s stock price today?
The current price of FRA:BXA0 is €1.55. The 52 week high of FRA:BXA0 is €1.85 and 52 week low is €0.71.
When is next earnings date of Lavipharm SA(FRA:BXA0)?
The next earnings date of Lavipharm SA(FRA:BXA0) is .
Does Lavipharm SA(FRA:BXA0) pay dividends? If so, how much?
The Dividend Yield %  of Lavipharm SA(FRA:BXA0) is 1.29% (As of Today), Highest Dividend Payout Ratio of Lavipharm SA(FRA:BXA0) was 0.71. The lowest was 0.69. And the median was 0.71. The  Forward Dividend Yield % of Lavipharm SA(FRA:BXA0) is 1.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Lavipharm SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers